(b) whether it is a fact that the cases of overcharging of price of Erythromycin by Menta Pharmaceuticals and of Ampicilline Sodium Sterile by M/s. Armour have not been brought to the notice of Government;

(c) if so, the details thereof;

(d) whether it is also a fact that these cases have delieberately been ignored at the meetings of sub-committee of the DPRC as well as in his Ministry;

(e) if so, the reasons therefor;

(f) whether it is also a fact that number of other cases of overcharging have been suppressed; and

(g) if so, what are the details of those cases and what are the reasons for letting them off?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The details of cases in which the tentative amount of overcharging of prices have been worked out, were given in reply to Rajya Sabha Unstarred Question No. 650 answered on 5-9-91. The details to the extent available, of all the cases of overcharging of prices of bulk drugs and formulations which came to the notice of the Govt. after promulgation of DPCO, 1987, upto 15th February, 1992 were given in reply to Rajya Sabha Unstarred Question No. 418 answered on 27th February, 1992.

(b) and (c) To the extent information available, no complaint has been brought to the notice of Government regarding overcharging of price of Erythromycin by M/s. Mehta Pharmaceuticals and of Ampicillin Sodium Stearate by M/s. Armour.

(d) and (e) DPRC Sub-committee has worked out the prices of formulation of these drugs on the basis of notified prices of these bulk drugs.

(f) No, Sir.

(g) Does not arise.

Report of Bhatti Committee

3791. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 2067 given in Rajya Sabha on 12th December, 1991 and state:

(a) whether it is a fact that final report of Bhatti Committee is yet to be received by Government;

(b) if so, by when it is expected;

(c) whether it is a fact that full payments have been released to Bhatti Committee from DPE Account;

(d) if so, when;

(e) whether it is also a fact that the Committee did not study the issue of adequacy or inadequacy of Trade Commission but merely carried out the survey to which there was no response;

(f) if so, the reasons therefor; and

(g) what is the relevance and connection of survey of Trade Commission with DPEA and how does it serve the cause of DPEA?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Yes, Sir.

(b) The Director General, National Council for Applied Economic Research has been requested to expedite submission of the final Report to the Government.

(c) No, Sir.

(d) Does not arise.

(e) No, Sir.

(f) Does not arise.

(g) As already stated in reply to Rajya Sabha Unstarred Question No. 677 answered on 28-11-1991, Drug Price Equalisation Account (DPEA) could be used for processing of matters (including incurring of expenditure) which relates to the Drug Industry as a whole.

Monitoring the production of bulk drugs

3792. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to refer the answer to Unstarred Question 1342 given in Rajya Sabha on 5th December, 1991 and state:

(a) what are the names of bulk drugs production of which is being monitored by Government and what was the production of each during the last three years, year-wise;

(b) how many persons have been deployed for monitoring the production by Government and what are their ranks and annual salary;

(c) what are the names of Bulk Drugs for which PMP was laid down by Government and what are the details of PMP in the case of each Bulk Drugs;